Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00536705|
Recruitment Status : Completed
First Posted : September 28, 2007
Last Update Posted : July 27, 2011
|Condition or disease||Intervention/treatment|
The majority pediatric asthma patients in Shanghai are mild persistent asthma. These patients require controller medications every day to achieve and maintain control. Leukotriene receptor antagonist is one of the options which have been recommended to use as a mono controller therapy. Patient satisfaction and compliance was better with montelukast, attributed to oral intake and convenience. Owing to its easy and simple oral once a day administration montelukast was found to be advantageous over ICS. On the other hand, recent studies have shown that there is a considerable degree of airway remodeling in peripheral airways in patients with mild asthma.The new information points out the need for large, long term studies on the treatment of mild persistent asthma, with an emphasis on exacerbations, remodeling, and the relationship between these outcomes and markers of asthma control. TGF-β participates in the initiation and propagation of inflammatory and immune responses in the airways. The leukotrienes exert their biologic actions by binding to and activating specific receptors. Montelukast, a cysteinyl leukotriene 1(CysLT1) receptor antagonist, acts on LTC4, LTD4 and LTE4, and, therefore, on airway inflammation and bronchoconstriction. Some results suggest that low dose of Montelukast may modulate the parameters of inflammation and fibrosis.In this study we try to determine the effects of lower dose Montelukast on the expression and variation of TGF-β in induced sputum and T lymphocyte for children with mild persistent Asthma.
Drug in the study provide by MSD. We have done induced sputum procedure in our past study. Reagent can be bought from company.
|Study Type :||Observational|
|Actual Enrollment :||112 participants|
|Observational Model:||Case Control|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||March 2011|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00536705
|Shanghai First People'S Hospital|
|Shanghai, Shanghai, China, 200080|
|Principal Investigator:||hong jianguo, prof||pediatric of shanghai jiantong University|